secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protalix BioTherapeutics, Inc. (PLX)
CIK:        0001006281
Form:       8-K
Filed at:   2023-09-12T23:59:59+00:00
Accession:  0001558370-23-015635
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protalix appoints Eliot Richard Forster as Chairman; Zeev Bronfeld retires
--------------------------------------------------------------------------

- Forster appointed Chairman and independent director effective Sept 14, 2023; also joins Nominating Committee.
- Zeev Bronfeld retires as Chairman after nearly three decades; cites recent drug approval as transition point.
- Forster receives 10-year option for 85,715 shares vesting quarterly over 3 years and $70,000 annual fee.
- Forster is non-executive chairman of Avacta Group and director of Immatics NV; former CEO of F-Star Therapeutics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006281/000155837023015635/0001558370-23-015635-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006281/000155837023015635/plx-20230912x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-015635

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer